What is Geneoscopy?
Geneoscopy Inc. is at the forefront of developing innovative diagnostic tests for gastrointestinal health, with a particular focus on colorectal cancer. Their lead diagnostic utilizes stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This groundbreaking device has received Breakthrough Device Designation from the U.S. FDA, highlighting its potential to significantly reduce morbidity associated with colorectal cancer through enhanced adenoma detection. Preliminary trials indicate a superior detection rate for these lesions compared to existing noninvasive screening methods, positioning Geneoscopy as a key player in the diagnostics sector.
How much funding has Geneoscopy raised?
Geneoscopy has raised a total of $217.1M across 4 funding rounds:
Series A
$6.9M
Debt
$150K
Series B
$105M
Series C
$105M
Series A (2019): $6.9M with participation from Cultivation Capital, NT Investments, and Lightchain Capital LLC
Debt (2020): $150K led by PPP
Series B (2021): $105M supported by Nt Investment Academy and Lightchain
Series C (2025): $105M featuring Granger Management, PETRICHOR Group, Lightchain Capital, Bio-Rad Laboratories, Mercy Health, Labcorp, Tri Locum Partners, and Morningside Ventures
Key Investors in Geneoscopy
Nt Investment Academy
Nt Investment Academy, operating in the Fitness & Dance Facilities industry, has participated in Geneoscopy's funding rounds. While its primary domain is unrelated to life sciences, its investment suggests a diversified portfolio strategy or a specific interest in the company's growth potential.
Lightchain
Lightchain, a UK-based IT delivery company focused on person-centric technology solutions, has backed Geneoscopy. This investment may reflect an interest in the intersection of technology and healthcare innovation, supporting companies that leverage advanced solutions.
Bio-Rad Laboratories
Bio-Rad Laboratories, a global leader in life science research and clinical diagnostic products, has invested in Geneoscopy. This strategic backing aligns with Bio-Rad's commitment to advancing diagnostic technologies and supporting companies that enhance laboratory efficiency and diagnostic accuracy.
What's next for Geneoscopy?
With the recent major strategic investment, Geneoscopy is poised for significant expansion and further development of its diagnostic technologies. The substantial capital raised, indicated by $217.1M, suggests the company is in a scaling phase, likely Series B or C, enabling it to broaden its clinical trial reach, enhance manufacturing capabilities, and strengthen its commercialization efforts. This strategic financing will be crucial for Geneoscopy to solidify its market position and bring its advanced colorectal cancer screening solutions to a wider patient population, aiming to improve health outcomes globally.
See full Geneoscopy company page
